**Table S1. Clinical and molecular characteristics of patients included in TCGA and CGGA dataset.**

|  |  |  |
| --- | --- | --- |
| **Cohort** | **CGGA-RNAseq****(n = 1038)** | **TCGA-RNAseq****(n = 672)** |
| **Age, years** |  |  |
| Mean (range) | 43 (8 – 79) | 47 (14 – 89) |
| **Gender** |  |  |
|  Female | 417 | 283 |
|  Male | 601 | 384 |
|  Unavailable | 0 | 5 |
| **Primary or recurrent** |  |  |
|  Normal | 20 | 5 |
|  Primary glioma | 651 | 641 |
|  Recurrent glioma | 333 | 26 |
|  Secondary GBM | 30 | 0 |
|  Unavailable | 4 | 5 |
| **WHO Grade** |  |  |
|  Normal | 20 | 5 |
|  Grade II | 291 | 250 |
|  Grade III | 334 | 262 |
|  Grade IV | 388 | 155 |
|  Unavailable | 5 | 0 |
| **Histology** |  |  |
|  Normal | 20 | 5 |
|  Oligodendroglioma | 112 | 114 |
|  Oligodendroglioma, anaplastic | 94 | 79 |
|  Astrocytoma | 175 | 63 |
|  Astrocytoma, anaplastic | 214 | 128 |
|  Oligoastrocytoma | 9 | 128 |
|  Oligoastrocytoma, anaplastic | 21 | 0 |
|  Glioblastoma | 388 | 155 |
|  Unavailable | 5 | 0 |
| **IDH status** |  |  |
|  Mutant | 531 | 126 |
|  Wild-type | 435 | 296 |
|  Unavailable | 72 | 250 |
| **1p/19q status** |  |  |
|  Codel | 212 | 0 |
|  Non-codel | 728 | 0 |
|  Unavailable | 98 | 672 |
| **Overall survival, days** |  |  |
|  Median | 1280 | 855 |
| **Survival status** |  |  |
|  Alive | 362 | 408 |
|  Dead | 617 | 256 |
|  Unavailable | 59 | 8 |